METASTX, LLC
MetasTx is dedicated to creating novel therapeutics to treat and prevent cancer metastasis, focusing on inhibiting PAK-1 enzyme activity to halt the spread of solid tumors such as prostate, breast, and skin cancers. Their innovative approach aims to improve patient survival and quality of life by targeting the metastatic process at its core with highly selective and stable formulations like MTX-101.
Industries
Nr. of Employees
small (1-50)
Products
MTX-101 (liposomal encapsulated allosteric PAK inhibitor)
A sterically stabilized nano‑liposomal formulation of an allosteric Group‑1 PAK inhibitor developed to increase plasma stability, extend half‑life, and concentrate drug delivery to solid tumors to inhibit metastatic processes.
MTX-101 (liposomal encapsulated allosteric PAK inhibitor)
A sterically stabilized nano‑liposomal formulation of an allosteric Group‑1 PAK inhibitor developed to increase plasma stability, extend half‑life, and concentrate drug delivery to solid tumors to inhibit metastatic processes.
Services
Preclinical efficacy studies
Design and execution of in vitro and in vivo experiments to evaluate anti‑metastatic activity of candidate compounds in tumor and bone metastasis models.
Liposomal formulation development
Development of sterically stabilized liposomal formulations to improve stability, half‑life, and tumor targeting of labile small molecules.
Preclinical efficacy studies
Design and execution of in vitro and in vivo experiments to evaluate anti‑metastatic activity of candidate compounds in tumor and bone metastasis models.
Liposomal formulation development
Development of sterically stabilized liposomal formulations to improve stability, half‑life, and tumor targeting of labile small molecules.
Expertise Areas
- Preclinical oncology drug development
- Liposomal and nanoparticle drug delivery
- Allosteric kinase inhibitor discovery
- EMT/MET biology and metastasis mechanisms
Key Technologies
- Sterically stabilized liposomes
- Nanoparticle passive tumor targeting (EPR)
- Allosteric small‑molecule kinase inhibition
- In vitro EMT/MET cellular assays